Description: Session 5B: The Evolving World of Biosimilars

Description: The coming wave of biosimilars could have a major impact on prescription drug spend in coming years. The big event of Humira biosimilar launches in 2023 will be significant in determining that ultimate impact. Payers are making coverage decisions. The more biosimilars are utilized, the greater the potential savings. How will biosimilar adoption be maximized?

Description: A brief review of the 2024 SOA Health Meeting in Baltimore

Description: Recording for ACA Challenges in a More Robust Enrollment Environment

Description: A comprehensive primer on long-term care wellness programs, their design, implementation, challenges, metrics for success, and emerging industry practices.

Description: The health care sector in general, and physicians in particular, are a large and important part of the market for group and individual insurance products. Explore a variety of subjects related to physicians and disability insurance, including experience trends, purchasing trends, external factors affecting physicians, and the impact of the COVID-19 pandemic.

Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: The cost of prescription drugs is top of mind for consumers, payers and policymakers. Despite legislative efforts, such as the Inflation Reduction Act, the problem remains. More than 30% of all Americans say they have not taken prescription drugs as prescribed in the last 12 months because of the expense. The purpose of this paper is to discuss an alternative to policy solutions: reimagining pharmacy financing in the commercial space using a value-based reimbursement methodology that increases transparency, encourages competition, aligns stakeholder incentives and mitigates total cost of care (TCOC) increases. This paper will demonstrate that it is possible to implement such a methodology under the current infrastructure, but one can identify limitations.

Description: An in-depth analysis of the insurance landscape in China and seven key Asia Pacific Markets, focusing on the rapid development of critical illness products and the impact of technology on insurance purchasing behaviors.